Key words: chronic renal failure; hepatitis B revaccination; interleukin-2 Background. Growing evidence suggests that it is possible to seroconvert chronic renal failure patients who are absolute non-responders to hepatitis B vaccine by means of either additional booster vaccine doses or associated IL-2 administration or both. We have Introduction studied the possibilities of hepatitis B seroconversion by revaccination and its dependence on vaccine dose, Hepatitis B vaccination is commonly carried out in and the effects of a concurrent low-dose rHuIL-2 most uraemic patients, whether haemodialysed or not. regime.
the vaccine dose and frequency of administration data from the remaining 40 patients entered in the present study have been evaluated. No side-effects to employed in uraemic patients should be higher than those usually administered to the normal population, IL-2 were encountered throughout the duration of the study. but a homogeneous policy has not yet been attained. Thus we subsequently encounter wide differences in Twenty-two patients ( 55%) had HBs antibody titres greater than 10 U/l at the end of the revaccination vaccination methodology between authors in this field [9, 10] .
programme. Revaccination was more frequently successful in the group receiving 40-mg doses than in the The aims of this prospective study carried out on non-responder chronic renal patients were to evaluate group receiving 20-mg doses ( 67 vs 20%, P=0.025) (Table 1 ) . the effects of vaccine dose and of simultaneously administered rHuIL-2.
Analysis of the effect of IL-2 administration in successful responders revealed a higher number of responses in the group of IL-2-treated patients, but a Subjects and methods statistically significant difference could not be established (55 vs 45%, P=0.056). On multivariate analysis, Forty-five non-responder patients gave their written consent the independent correlate of response to vaccination and were entered in the study. 12 patients had been previously was dose of vaccine (OR, 3.3 (95% CI, 1.22 to 8.83)) vaccinated with three or more doses of 20 mg. The remaining (P=0.0182). Administration of IL-2 (OR, 2.1 (95% 33 patients had received three or more doses of 40 mg, as CI, 0.95 to 4.6)) (P=0.06), sex, or age were not indicated. statistically significant.
Those who had been vaccinated with doses of 20 mg before entering the present study were revaccinated with four doses When HCV seropositives and erythropoietinof 20 mg, while those who had previously received doses of receiving patients, both IL-2 treated and untreated 40 mg were revaccinated with four doses of 40 mg. S-HuR-HB cases were compared (6 patients with positive hepatitis vaccine (Engerix-B) was given in the deltoid region, sched-C virus serology, 4 responders vs 2 non-responders, uled at 0, 1, 2 and 6 months.
P=0.67; and 14 patients with erythropoietin treatment, IL-2 was administered in randomly selected patients from 7 responders vs 7 non-responders, P=0,64) no differboth the above dosage groups. Des-alanine-l, serine-125 non-ences in terms of antibody response could be observed. The anti-HBs antibody concentration was assayed at IL-2 (9±2% vs 31±11%, P=0.0003) but differences months 0, 1, 2, 3, 6 and 7 of the revaccination schedule by between basal and final levels were not observed. routine method using a commercially available test Th-CD4/CD25 counts declined after rHuIL-2 adminis-( IMxAUSAB, Abbot) Revaccination was considered success-tration. On the other hand, Th-CD4/CD25 expression ful when a HBs antibody titre higher than 10 U/l was was found to increase 1 month after the last dose of detected during the revaccination schedule up to month 7.
IL-2 had been given ( Table 2) . Dickinson, Mountain View, USA) using commercially avail-When given to dialysed and non-dialysed patients with able monoclonal antibodies (Becton Dickinson), quantitative chronic renal failure, and in spite of its widespread analysis of CD3, CD4, CDS, CDl9, CD4/cD25, and use, hepatitis B vaccination has not led to successful cD8/CD25 membrane antigen expression was carried out on prevention of HBV infection in this group of patients. 1,500-2,000 lymphoid cells, obtained at three stages of the It is currently agreed that only 50-60% of such patients vaccination schedule: at basal state before the first vaccine attain protective antibody levels to HBV of 10 U/l or dose, four h after the first dose of IL-2 and one month after higher. Until recently no novel strategies had been the last IL-2 dose was given.
advanced which might produce protective antibody Repeated measurements analysis was performed with titres in the 30-40% of remaining patients commonly Friedman and Wilcoxon tests. The x2 test was used for analysis of association between two categorical variables, using Yates' correction or Fisher exact test when appropiate. considered as permanently unresponsive [1] [2] [3] . In these inversely correlated to the IL-2-secreting capacity of the T-helper cell [3 ] . In the uraemic state, reduced patients, the prevention of hepatitis B virus infection is based on both HBsAg surveillance and the isolation IL-2 secretion may be responsible for inadequate progression and proliferation within the T-cell cycle. This of HBsAg carriers.
Currently the normal population is immunized is suggested by the increased proliferative capacity observed in fresh T-cells taken from uraemic subjects against HBV infection with 20 mgof vaccine administered three times [4] . This method is still employed to after the addition of low concentrations of exogenous IL-2 'in vitro' [7 ] . These findings suggest a potentially vaccinate uraemic patients, despite the low rates of protective antibody levels obtained. For the purposes beneficial effect imparted by IL-2 on the HBV antibody response of uraemic patients when administered in of this study we have accepted the currently agreed criteria and evaluated as unresponsive all patient lack-association with the HBV vaccine.
In a separate pilot study, six of only 10 noning an adequate antibody response level after receiving three vaccine doses of 20 mg each, administered at 0, 1 responder patients appeared to respond to concurrent IL-2 administration and HBV revaccination [8 ] . These and 6 months. Nevertheless, the possibility of an improved response by using four vaccine doses has encouraging results have not been confirmed by other groups [11] , and appreciable differences in the methods been suggested for these patients [9, 10] . Notable seroconversion rates have been documented in previous applied make them non-comparable to our present study. Our results may not demonstrate an enhanced non-responders after a booster revaccination dose is given [9, 11] . These findings may raise the possibility IL-2-mediated HBV antibody response, although cellular changes strongly indicative of a biological effect of wrongly classifying some patients as non-responders who could be classified as responders were they exposed due to rHuIL-2 are detected. The method we have used is similar but not identical to that described in to a larger amount of antigen [12 ] . Unfortunately an agreed policy with regards to a more effective HBV the preliminary report mentioned above, as highlighted below. We have given four (rather than two) doses of vaccination programme for chronic uraemic patients is yet to be established.
HBV vaccine at two different strengths, as well as IL-2. Furthermore, it is known that HBV vaccines vary in Unresponsiveness to the HBV vaccine has been ascribed to the immunodeficient state associated with immunogenicity according to the preparation [13 ] , as do the biological effects of IL-2 [14] . Thus, a difference uraemia, which is considered multifactorial in aetiology. Dysfunction of monocyte-related and Th-1 in the administered IL-2 effect, influencing the HBV antibody response rate, cannot be excluded between helper cell mechanisms that would result in impaired signalling to memory and antibody-forming cells have these two studies.
It has been suggested that erythropoietin therapy been postulated [5, 6] . The present study may suggest that defective monocyte antigen presentation associ-may enhance the HBV antibody response induced by vaccination [15] . However, our results do not point ated with low Th-1 cell TCR/CD3 antigen receptor recognition could participate in the HBV vaccine unre-towards any such associated erythropoietin effect.
Until new data are available, our results strongly sponsiveness eventually seen in many patients with chronic renal failure. It may also explain the higher suggest that HBV revaccination alone is effective in seroconverting many previously unresponsive uraemic response rate observed when four doses of a HBV vaccine each of 40 mg are implemented. Therefore our patients, and that stimulation with a larger HBV vaccine antigen dose may procure the highest HBV results indicate that revaccination may be effective and dose dependent even in those patients who had received antibody response rates. up to four doses of 40 mg in their initial immunization schedule.
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Another study has previously shown that the expres- 
